In vitro cytochrome p450 activity decreases in children with high pediatric end-stage liver disease scores

Drug Metabolism and Disposition

Volumn 41, Issue 2, 2013, Pages 390-397

  De Bock, Lies ^a   Boussery, Koen ^a   Van Wincke, Myriam ^b   De Paepe, Peter ^c   Rogiers, Xavier ^b   Stephenne, Xavier ^d   Soka, Etienne ^d   Van Bocxlaer, Jan ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CIPROFLOXACIN; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ESOMEPRAZOLE; FLUCONAZOLE; PROPRANOLOL; RETINOL; RIFAMPICIN; SOMATOSTATIN; SULFAMETHOXAZOLE;

ARTICLE; BILE DUCT ATRESIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFANT; LIVER DYSFUNCTION; LIVER MICROSOME; MALE; PEDIATRIC END STAGE LIVER DISEASE SCORE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DOWN-REGULATION; DRUG INTERACTIONS; DRUG THERAPY; END STAGE LIVER DISEASE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; ISOENZYMES; LIVER; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 84872706310     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048504     Document Type: Article

References (41)

1. Adam R and Hoti E (2009) Liver transplantation: the current situation. Semin Liver Dis 29:3-18.
2. Alcorn J and McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 41:959-998. (Pubitemid 35168438)
3. Barrett JS, Della Casa Alberighi O, Läer S, and Meibohm B (2012) Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 92:40-49.
4. Boobis A, Watelet JB, Whomsley R, Benedetti MS, Demoly P, and Tipton K (2009) Drug interactions. Drug Metab Rev 41:486-527.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. De Bock L, Boussery K, Colin P, De Smet J, T'jollyn H, and Van Bocxlaer JFP (2012a) Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity. Talanta 89:209-216.
7. De Bock L, Colin P, Boussery K, and Van Bocxlaer J (2012b) Development and validation of an enzyme-linked immunosorbent assay for the quantification of cytochrome 3A4 in human liver microsomes. Talanta 99:357-362.
8. de Wildt SN (2011) Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 7:935-948.
9. Elbekai RH, Korashy HM, and El-Kadi AOS (2004) The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 5:157-167. (Pubitemid 38515245)
10. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, and Branch RA (2006) Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 80:235-245. (Pubitemid 44313901)
11. Fuhr U, Anders EM, Mahr G, Sörgel F, and Staib AH (1992) Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36:942-948.
12. George J, Murray M, Byth K, and Farrell GC (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21: 120-128.
13. Hamman MA, Thompson GA, and Hall SD (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54:33-41. (Pubitemid 27353220)
14. Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250-267.
15. Hines RN (2007) Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 21: 169-175. (Pubitemid 350194376)
16. Ince I, de Wildt SN, Peeters MYM, Murry DJ, Tibboel D, Danhof M, and Knibbe CAJ (2012) Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit 34:381-389.
17. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, and Rostami-Hodjegan A (2010) A semimechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49:189-206.
18. Johnson TN and Rostami-Hodjegan A (2011) Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Pediatr Anesth 21:291-301.
19. Kauffman RE and Kearns GL (1992) Pharmacokinetic studies in paediatric patients: clinical and ethical considerations. Clin Pharmacokinet 23:10-29.
20. Knibbe CAJ and Danhof M (2011) Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm 415:9-14.
21. Knibbe CAJ, Krekels EHJ, and Danhof M (2011) Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol 7:1-8.
22. Kudo S, Uchida M, and Odomi M (1997) Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol 52:479-485. (Pubitemid 27395648)
23. Li XQ, Andersson TB, Ahlström M, and Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827. (Pubitemid 38955611)
24. Ma B, Prueksaritanont T, and Lin JH (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28:125-130. (Pubitemid 30068994)
25. McDiarmid SV, Anand R, and Lindblad AS; Principal Investigators and Institutions of the Studies of Pediatric Liver Transplantation (SPLIT) Research Group (2002) Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 74:173-181. (Pubitemid 34810283)
26. McLellan RA, Drobitch RK, Monshouwer M, and Renton KW (1996) Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 24:1134-1138. (Pubitemid 26346228)
27. Muiesan P, Vergani D, and Mieli-Vergani G (2007) Liver transplantation in children. J Hepatol 46:340-348. (Pubitemid 44959166)
28. Rasmussen E, Eriksson B, Oberg K, Bondesson U, and Rane A (1998) Selective effects of somatostatin analogs on human drug-metabolizing enzymes. Clin Pharmacol Ther 64: 150-159. (Pubitemid 28423850)
29. Rocchi F and Tomasi P(2011) The development of medicines for children (Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni). Pharmacol Res 64:169-175.
30. Rodriguez-Antona C and Ingelman-Sundberg M (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene 25:1679-1691.
31. Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, and Roots I (1992) Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52: 170-180.
32. Sokal EM, Goldstein D, Ciocca M, Lewindon P, Ni YH, Silveira T, Sibal A, Dhawan A, Mack C, and Bucuvalas J; End-Stage Liver Disease Working Group (2008) End-stage liver disease and liver transplant: current situation and key issues. J Pediatr Gastroenterol Nutr 47: 239-246.
33. Sousa M, Pozniak A, and Boffito M (2008) Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 62: 872-878.
34. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407. (Pubitemid 23320988)
35. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111-180. (Pubitemid 30122116)
36. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161.
37. Vet NJ, de Hoog M, Tibboel D, and de Wildt SN (2012) The effect of critical illness and inflammation on midazolam therapy in children. Pediatr Crit Care Med 13:e48-e50.
38. Villeneuve JP and Pichette V (2004) Cytochrome P450 and liver diseases. Curr Drug Metab 5:273-282. (Pubitemid 38735781)
39. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, and Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440. (Pubitemid 37188139)
40. Yamazaki H and Shimada T (1999) Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 29:231-241. (Pubitemid 29140093)
41. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319. (Pubitemid 35397032)